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EDITORIAL
Predictors  of  Severity  and  In-Hospital  Mortality  for
Acute Pancreatitis:  Is There  Any  Role for  C-Reactive
Protein Determination  in the First  24 Hours?
Fatores  Preditivos  de  Mortalidade  Intra-Hospitalar  na  Pancreatite  Aguda:
Haverá  Algum  Lugar  para  a  Determinac¸ão  da  Proteína-C  Reativa  nas
Primeiras  24  Horas?
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Acute  pancreatitis  (AP)  is  one  of  the  most  common  gas-
trointestinal  disorders,  with  a  reported  annual  incidence
of  13--45  cases  per  100,000  persons.1,2 It  is  a  complex  dis-
ease  that  can  vary  from  a  mild  self-limited  presentation,
in  approximately  80--90%  of  patients,  to  a  clinically  severe
form  in  10--20%  with  multiple  complications  and  a  mor-
tality  rate  up  to  30%.2--5 Timely  identiﬁcation  of  patients
with  clinically  severe  AP  and  worse  prognosis  is  impor-
tant  because  they  may  beneﬁt  from  prompt  admission  to
a  dedicated  intensive  or  intermediate  care  unit,  with  close
monitoring  for  the  development  of  organ  failure,  they  should
receive  aggressive  ﬂuid  resuscitation  and  targeted  ther-
apy  such  as  enteral  feeding,  endoscopic  sphincterotomy,  or
antibiotics.4,5 Severity  stratiﬁcation  is  also  important  when
reporting  and  evaluating  the  results  of  clinical  trials  in  AP.
The  Atlanta  Classiﬁcation  has  been  considered  the  global
standard  tool  for  the  assessment  of  AP  severity  since  its
establishment  in  1992.6 However,  this  classiﬁcation  was
somehow  confusing  and,  in  2012,  it  was  revised  with  a
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ﬁed  Marshall  scoring  system.3
An  ideal  prognostic  score  should  be  simple,  non-invasive,
ccurate,  quantitative,  and  the  assessment  methods  should
e  easily  applicable  at  the  time  of  diagnosis.7 By  this
oment  there  are  different  predictive  scoring  systems  for
cute  pancreatitis,  such  as  the  Acute  Physiology  And  Chronic
ealth  Evaluation  (APACHE)  II,  Ranson,  Bedside  Index  for
everity  in  Acute  Pancreatitis  (BISAP),  Simpliﬁed  Acute  Phys-
ology  Score  (SAPS)  II,  Harmless  Acute  Pancreatitis  Score
HAPS)  and  modiﬁed  Glasgow  score.2,8 Persistent  (>48  h)
ystemic  Inﬂammatory  Response  Syndrome  (SIRS)  is  also
ssumed  as  a  prognostic  factor  for  severe  acute  pancreati-
is.  However,  these  scores  are  complex  and  some  cannot
e  applied  at  any  time.  So,  nowadays  much  effort  has
een  concentrated  on  the  evaluation  of  single  serum  mark-
rs  (C-reactive  protein,  hematocrit,  procalcitonin,  blood
rea  nitrogen,  creatinine,  calcium,  hyperglycemia,  albu-
in,  interleukin-6),  clinical  variables  (age,  body  mass  index,
ntra-abdominal  pressure)  and  radiologic  signs  (pleural  effu-
ion,  CT  severity  index)  as  predictive  factors  for  worse
utcome.9
Amongst  the  multiple  biochemical  markers  the  C-reactive
rotein  (CRP)  is  probably  the  most  useful.8,10--12 It  is  accurate
nd  widely  available  but  it  is  generally  accepted  that  its
aximum  level  occurs  not  earlier  than  72  h  after  the  onset
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f  symptoms.8 The  majority  of  authors/guidelines  assume
hat  a  CRP  level  at  48  h  after  onset  of  symptoms  ≥150  mg/l
s  a  bad  prognostic  predictor.8,9,13--15
Despite  the  simplicity  and  easy  availability  of  CRP  in  clin-
cal  practice,  many  studies  have  described  a  limitation  of
linical  utility  of  this  biochemical  parameter  in  the  early
hase  of  AP,  since  CRP  alone  can  potentially  fail  to  detect
evere  cases  of  AP  at  an  earlier  stage.7,16,17
In  this  issue  of  GE  Portuguese  Journal  of  Gastroen-
erology,  Cardoso  et  al12 report  the  potential  utility  of
RP  determination  in  the  ﬁrst  24  h  as  a  predictor  of  in-
ospital  mortality  for  AP.  This  is  a  retrospective  study,
nvolving  134  patients,  with  nine  deaths  (6.7%)  during  hos-
ital  admission.  The  median  overall  CRP  level  at  24  h  was
04.4  (inter-quartile  range,  29.2--191.2  mg/l)  and  this  bio-
hemical  parameter  was  higher  in  patients  who  died  during
ospital  stay  (197.2  vs.  100.2,  p  =  0.003).  In  univariate  anal-
sis  the  odds  ratio  of  CRP  at  24  h  for  prediction  of  in-hospital
ortality  was  1.11  (95%  CI,  1.04--1.17)  and  the  correspond-
ng  AUC  was  0.80  (95%  CI,  0.65--0.95).  It  is  interesting  to
otice  that  none  of  the  46  patients  with  CRP  levels  at  24  h
ower  than  60  mg/l  died  and  only  one  of  the  nine  patients
ith  severe  acute  pancreatitis  had  a  CRP  level  lower  than
hat  potential  cut-off.  On  the  other  side,  the  addition  of  CRP
o  BISAP  reduced  the  calculated  risk  of  in-hospital  mortality
n  about  42%  of  patients  who  survived  but  the  overall  effect
as  not  statistically  signiﬁcant.
This  study  suggests  that  an  early  determination  of  CRP,
n  the  ﬁrst  24  h  of  admission,  could  have  a  good  individual
rognostic  accuracy  for  in-hospital  survival.  Using  a  cut-off
f  60  mg/l  the  sensitivity  for  detecting  patients  that  will
urvive  to  this  episode  was  100%  but  the  positive  predic-
ive  value  was  only  10%.  Also  interesting  is  the  suggestion
hat  a  combination  of  CRP  and  BISAP  could  help  to  reclas-
ify  patients  at  low  risk  to  die  from  acute  pancreatitis  or
ts  complications  during  index  hospital  stay,  although  the
bserved  tendencies  did  not  achieve  statistical  signiﬁcance.
However,  the  results  and  conclusions  presented  by  the
uthors  had  several  limitations:  the  study  is  retrospective;
here  are  only  nine  deaths  during  admission;  data  on  organ
ailure  were  available  for  70  patients;  other  scoring  sys-
ems  such  as  APACHE  II  were  not  considered;  the  authors
resented  no  data  about  CRP  levels  at  48  h  and  potential
ifferences  with  CRP  at  24  h.
There  are  few  studies  about  the  clinical  utility  of  CRP  at
4  h.  A  recent  study  by  Cho  et  al  demonstrated  that  a CRP
evel  ≥214  mg/l  at  24  h  after  admission  was  positively  asso-
iated  with  an  increased  risk  of  severe  acute  pancreatitis.7
n  the  present  study  no  clear  cut-off  was  established  and  it
s  interesting  to  notice  that  the  same  authors,  Cardoso  et
l,  had  already  demonstrated  that  CRP  at  48  h  after  hospi-
al  admission  showed  a  good  prognostic  accuracy  for  severe
cute  pancreatitis  and  in-hospital  mortality.12 By  the  con-
rary,  procalcitonin  could  be  used  as  predictor  of  severe
cute  pancreatitis  in  the  ﬁrst  24  h.18 Unfortunately,  the
tudy  published  today  in  GE  did  not  consider  this  variable.
So,  CRP  could  be  an  interesting  alternative  to  more  com-
lex  scoring  systems.  However,  recent  guidelines  from  the
nternational  Association  of  Pancreatology  and  the  Amer-
can  Pancreatic  Association  discourage  the  routine  use
f  single  markers,  such  as  CRP,  hematocrit,  blood  urea
itrogen  or  procalcitonin  alone  to  triage  patients  to  an
1N.  Almeida  et  al.
ntensive  care  setting.2 The  guidelines  from  the  American
ollege  of  Gastroenterology  also  assume  that  no  laboratory
est,  including  CRP,  is  practically  available  or  consistently
ccurate  to  predict  severity  in  patients  with  acute
ancreatitis.17 Although  all  scoring  systems  have  been  shown
o  correlate  with  morbidity  and  mortality,  it  remains  difﬁcult
o  accurately  identify  individual  patients  who  develop  clin-
cally  severe  disease  on  admission  or  early  in  the  course  of
heir  hospitalization.  However,  APACHE  II  and  persistent  SIRS
emain  the  best  markers  for  predicting  both  severity  and  in-
ospital  mortality.2,4,7,9,19,20 From  the  interpretation  of  the
ajority  of  studies  we  can  assume  that  no  simple  scoring  sys-
em  is  capable  of  reaching  maximal  utility  for  prediction  of
P  severity  and  in-hospital  mortality.  Unique  and  preferen-
ially  simple  models  are  needed  in  order  to  achieve  further
mprovement  in  this  ﬁeld  of  clinical  practice.  A  multicen-
ric,  prospective  study  is  urgently  needed  in  Portugal,  in
rder  to  determine  which  biochemical  parameters,  clinical
ariables  and/or  prognostic  scores  are  best  suited  to  iden-
ify  patients  with  higher  risk  of  complications  and  in-hospital
ortality.  These  patients  should  be  prematurely  referred  to
edicated  intermediate  or  intensive  care  units,  in  hospitals
ere  endoscopic,  radiologic  and  surgical  interventions  are
asily  available.
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